hexhead - Slashdot User

Comment Debian to the rescue (Score 4, Interesting) 815

by hexhead on Tuesday March 05, 2013 @09:16PM (#43087045) Attached to: Gnome Founder Miguel de Icaza Moves To Mac

After developing with Mac OSX for a year using the command line interface (i.e., lots of terminals), I found I needed some sort of ports-like package management which has its own headaches. After jacking around with seemingly never-ending updates to Ubuntu and it's resource hungry UI, I found Debian quite refreshing. Not on the bleeding edge, but this is a GOOD THING! Never regretted it.

Comment Sour Grapes (Score 2) 480

by hexhead on Sunday November 20, 2011 @12:32PM (#38116870) Attached to: Andrew Tanenbaum On Minix, Linux, BSD, and Licensing

Tanenbaum: These grapes are so very sour.

What a baby! I was once impressed by his move to create an alternative to commercial unices, but now I just want this guy to go away play with his own toys. Typical elitist academic.

Comment Re:I Want My Flying Car... (Score 1) 308

by hexhead on Tuesday November 30, 2010 @12:02PM (#34389360) Attached to: Ray Kurzweil's Slippery Futurism

You are criticizing HIS predictions when you are predicting 100 years in the future?

Renowned Geneticist Analyzes Consumer DNA Tests 97

Posted by kdawson on Tuesday June 16, 2009 @11:43PM from the all-in-the-interpretation dept.

pdragon04 sends in the hardly surprising news that direct-to-consumer genetic testing isn't predicting diseases as well as they claim. "...[Francis] Collins, who played a central role in the Human Genome Project and is rumored to be the next head of the National Institutes of Health, announced at the Consumer Genetics Conference in Boston last week that he had had his genome analyzed [using a made-up name] by the big three of direct-to-consumer genetic testing: 23andMe, Navigenics, and DecodeMe. Collins said that sequence-wise, the tests 'appear to be highly accurate': there were almost no differences in the genotype information generated in the three different analyses. But there were significant differences in the numbers of genetic variations used to calculate disease risk, as well as the final risk score. ... For example, one company used 5 single nucleotide polymorphisms, or SNPs, to calculate risk for a particular disease, pronouncing Collins at low risk. Another used 10 SNPs, placing him at high risk, and the third used 15, concluding that he is at average risk."

Slashdot Top Deals